Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman(University of Oxford), Adrian F. Hernandez(Duke University), M. Angelyn Bethel(Chinese University of Hong Kong), Robert J. Mentz(Duke University), Neil R Poulter(Imperial College London), Stephanie M. Gustavson(Chinese University of Hong Kong), Aldo P. Maggioni(Health Care Foundation), Neha J. Pagidipati(Duke University), Vivian P. Thompson(Duke University), Bernard Zinman(Mount Sinai Hospital), Juliana C.N. Chan(Chinese University of Hong Kong), Ambady Ramachandran(Chinese University of Hong Kong), Yuliya Lokhnygina(Clinical Research Institute), Nayyar Iqbal(Chinese University of Hong Kong), Jasmine Choi(Chinese University of Hong Kong), Steven P. Marso(Chinese University of Hong Kong), Peter Öhman(Chinese University of Hong Kong), John B. Buse(Unknown)
Cited by 2,133
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k